. Author manuscript; available in PMC: 2013 Sep 12.

Published in final edited form as: Am J Physiol Heart Circ Physiol. 2008 Apr 18;294(6):H2743–H2749. doi: 10.1152/ajpheart.91487.2007

TABLE 1.

Metabolic parameters in treatment groups

	Wistar + Vehicle (n=8)	Wistar + Atrasentan (n=10)	Wistar + A-192621 15 mg/kg (n=5)	Wistar + A-192621 30 mg/kg (n=5)
Weight (g)	506 ± 13	474 ± 29	500 ± 13	406 ± 2^b
Glucose (mg/dl)	114 ± 5	89 ± 3	109 ± 4	104 ± 5
Insulin (ng/ml)	2.7 ± 0.6	2.1 ± 0.3	2.2 ± 0.5	2.2 ± .72
ET-1 (fmol/ml)	0.3 ± 0.1	0.4 ± 0.2	0.3 ± 0.2	1.6 ± 0.5^b
MAP (mmHg)	103 ± 5	105 ± 5	107 ± 2	121 ± 3^c
	GK+ Vehicle (n=8)	GK + Atrasentan (n=8)	GK + A-192621 15 mg/kg (n=5)	GK + A-192621 30 mg/kg (n=5)
Weight (g)	362 ± 8^a	357 ± 10^a	354 ± 6^a	322 ± 10^a
Glucose (mg/dl)	207 ± 33^a	172 ± 17^a	304 ± 17^a	173 ± 31^a
Insulin (ng/ml)	1.0 ± 0.3^a	0.7 ± 0.1^a	0.9 ± 0.2^a	0.6 ± 0.1^a
ET-1 (fmol/ml)	0.9 ± 0.2^a	1.2 ± 0.1^a	1.4 ± 0.2^a	2.3 ± 0.3^a,^b
MAP (mmHg)	103 ± 4	106 ± 3	108 ± 3	116 ± 2^c

p<0.001 vs Wistar

p<0.001 vs vehicle, Atrasentan or A-192621 15 mg/kg

p<0.01 vs vehicle, Atrasentan or A-192621 15 mg/kg